Preclinical evidence also suggests that anti-LAG-3 is synergistically efficacious when combined with anti-PD-1.18 In addition, combination therapy with anti-LAG-3 and anti-PD-1 has provided remarkable clinical benefits to patients with melanoma.19 However, the efficacy of dual LAG-3 and PD-1 blockade in pediatric patients is still unknown. This evidence concerns the gene LAG3 and melanoma.